Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Interest & Investment Income (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Interest & Investment Income for 12 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Interest & Investment Income rose 15.87% year-over-year to $1.1 million, compared with a TTM value of $4.6 million through Sep 2025, up 109.8%, and an annual FY2024 reading of $3.3 million, up 197.07% over the prior year.
  • Interest & Investment Income was $1.1 million for Q3 2025 at Avalo Therapeutics, up from $1.1 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.2 million in Q4 2024 and bottomed at -$1.6 million in Q3 2023.
  • Average Interest & Investment Income over 5 years is -$173315.8, with a median of -$239000.0 recorded in 2021.
  • The sharpest move saw Interest & Investment Income crashed 6976.47% in 2022, then skyrocketed 1401.23% in 2024.
  • Year by year, Interest & Investment Income stood at -$1.2 million in 2021, then grew by 19.85% to -$949000.0 in 2022, then skyrocketed by 108.54% to $81000.0 in 2023, then surged by 1401.23% to $1.2 million in 2024, then dropped by 8.14% to $1.1 million in 2025.
  • Business Quant data shows Interest & Investment Income for AVTX at $1.1 million in Q3 2025, $1.1 million in Q2 2025, and $1.1 million in Q1 2025.